南京新百(600682.SH)擬發行股份及支付現金購買藍海科瑞100%股權 發行價10.28元/股
格隆匯11月6日丨南京新百(600682.SH)公佈,公司擬以發行股份及支付現金方式購買盈鵬蕙康持有的藍海科瑞99.9993%的財產份額,並通過上市公司全資子公司山東丹卓生物科技有限公司以支付現金方式購買盈鵬資產持有的藍海科瑞0.0007%的財產份額。本次交易完成後,藍海科瑞將成為上市公司的全資子公司。
本次發行股份購買資產發行的股份種類為境內上市人民幣普通股(A股),每股面值為人民幣1.00元,發行股份對象為盈鵬蕙康,發行價格為10.28元/股。
上市公司擬向不超過10名特定投資者非公開發行股份募集配套資金,本次募集配套資金總額不超過本次交易中以發行股份方式購買資產的交易價格的100%且發行股份數量不超過發行前公司股本總額的20%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.